Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy

American Journal of Roentgenology

Volumn 196, Issue 3, 2011, Pages 569-576

  Ng, Chaan S ^a   Charnsangavej, Chuslip ^a   Wei, Wei ^a   Yao, James C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bevacizumab; Carcinoid metastases; Interferon; Perfusion CT

Indexed keywords

BEVACIZUMAB; IOVERSOL; PEGINTERFERON ALPHA2B;

ADULT; AGED; ARTICLE; BLOOD VOLUME; CARCINOID; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; METASTATIC CARCINOID TUMORS; PERFUSION COMPUTER ASSISTED TOMOGRAPHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOID TUMOR; CONTRAST MEDIA; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON ALFA-2B; LIVER NEOPLASMS; MALE; MIDDLE AGED; TOMOGRAPHY, X-RAY COMPUTED; TRIIODOBENZOIC ACIDS;

EID: 79952258166     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.4455     Document Type: Article

References (31)

1. Miles KA. Functional computed tomography in oncology. Eur J Cancer 2002; 38:2079-2084 (Pubitemid 35223245)
2. Kambadakone AR, Sahani DV. Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am 2009; 47:161-178
3. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR 2004; 183:1619-1628 (Pubitemid 44210530)
4. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21:2689-2696 (Pubitemid 46606312)
5. Schnirer II, Yao JC, Ajani JA. Carcinoid: a comprehensive review. Acta Oncol 2003; 42:672-692 (Pubitemid 37445288)
6. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90: 687-693 (Pubitemid 36760596)
7. Tamm EP, Kim EE, Ng CS. Imaging of neuroendocrine tumors. Hematol Oncol Clin North Am 2007; 21:409-432, vii
8. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26: 1316-1323
9. Tannir NM, Cohen L, Wang X, et al. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006; 107:2254-2261 (Pubitemid 44665661)
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
11. Balter JM, Lam KL, McGinn CJ, Lawrence TS, Ten Haken RK. Improvement of CT-based treatment-planning models of abdominal targets using static exhale imaging. Int J Radiat Oncol Biol Phys 1998; 41:939-943 (Pubitemid 28285976)
12. Seppenwoolde Y, Shirato H, Kitamura K, et al. Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int J Radiat Oncol Biol Phys 2002; 53:822-834 (Pubitemid 34722626)
13. Lee TY. Functional CT: physiological models. Trends Biotechnol 2002; 20:S3-S10
14. Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998; 58:808-814 (Pubitemid 28099496)
15. von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95:437-448 (Pubitemid 36432418)
16. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91:1198-1205 (Pubitemid 24058977)
17. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67:227-264 (Pubitemid 28411130)
18. Sondak VK. How does interferon work? Does it even matter? Cancer 2002; 95:947-949 (Pubitemid 34925342)
19. Ng CS, Wang X, Faria SC, Lin E, Charnsangavej C, Tannir NM. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR 2010; 194:166-171
20. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147 (Pubitemid 38524883)
21. Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 2008; 13:120-125 (Pubitemid 351342575)
22. Sahani DV, Kalva SP, Hamberg LM, et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 2005; 234:785-792 (Pubitemid 40250822)
23. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-1027 (Pubitemid 46202320)
24. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390
25. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003; 89:1889-1895 (Pubitemid 37533265)
26. Marzola P, Degrassi A, Calderan L, et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005; 11:5827-5832 (Pubitemid 41170309)
27. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21:4428-4438 (Pubitemid 46621821)
28. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21:3955-3964 (Pubitemid 46606209)
29. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23:5464-5473
30. Evelhoch JL, LoRusso PM, He Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004; 10:3650-3657 (Pubitemid 38697598)
31. Goh V, Halligan S, Hugill JA, Gartner L, Bartram CI. Quantitative colorectal cancer perfusion measurement using dynamic contrast-enhanced multidetector-row computed tomography: effect of acquisition time and implications for protocols. J Comput Assist Tomogr 2005; 29:59-63 (Pubitemid 40194439)